J. Udosen, E. Akwiwu, Valerie. E Njar, D. Akpotuzor, J. Akpotuzor
{"title":"接受化疗的乳腺癌患者的血细胞缺陷比例","authors":"J. Udosen, E. Akwiwu, Valerie. E Njar, D. Akpotuzor, J. Akpotuzor","doi":"10.59708/ajlhts.v2i2.2309","DOIUrl":null,"url":null,"abstract":"Introduction: Anaemia, leucopenia and thrombocytopenia are at the forefront of haematological derangements encountered in the management of breast cancer. However, there is a gap in knowledge regarding their degree of occurrence at different stages of chemotherapy. Methods: Longitudinal design and purposive sampling technique were adopted to enroll 50 adult female breast cancer patients who were accessing chemotherapy at the University of Calabar Teaching Hospital in Calabar, Cross River State of Nigeria. Ethical approval and informed consent were duly obtained. The blood cell counts were carried out by automation. Frequencies of anaemia, leucopenia and thrombocytopenia were calculated after applying cut-off point using age- and gender-specific refence ranges (<120 g/l of Haemoglobin concentration for anaemia, <4.0 x 109/l of total white blood cell count for leucopenia and <150 x 109/l of platelet count for thrombocytopenia). Results: A greater number of the subjects had anaemia with prevalence ranging from 78% at the onset to 100% by the fifth course. Leucopenia ranged from 14% at the beginning to 100% by the third course. Thrombocytopenia was not present at pre-chemotherapy stage but appeared slightly (4%) during the assessment for second treatment course and rose to 55% at the last assessment. Conclusion: This study observed increasing proportions of cytopenia in association with progressing chemotherapy. There is high prevalence of anaemia in breast cancer even before commencement of chemotherapy, while leucopenia develops more rapidly during chemotherapy.","PeriodicalId":380612,"journal":{"name":"African Journal of Laboratory Haematology and Transfusion Science","volume":"37 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Proportions of Blood Cell Deficits in Breast Cancer Patients Undergoing Chemotherapy\",\"authors\":\"J. Udosen, E. Akwiwu, Valerie. E Njar, D. Akpotuzor, J. Akpotuzor\",\"doi\":\"10.59708/ajlhts.v2i2.2309\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Anaemia, leucopenia and thrombocytopenia are at the forefront of haematological derangements encountered in the management of breast cancer. However, there is a gap in knowledge regarding their degree of occurrence at different stages of chemotherapy. Methods: Longitudinal design and purposive sampling technique were adopted to enroll 50 adult female breast cancer patients who were accessing chemotherapy at the University of Calabar Teaching Hospital in Calabar, Cross River State of Nigeria. Ethical approval and informed consent were duly obtained. The blood cell counts were carried out by automation. Frequencies of anaemia, leucopenia and thrombocytopenia were calculated after applying cut-off point using age- and gender-specific refence ranges (<120 g/l of Haemoglobin concentration for anaemia, <4.0 x 109/l of total white blood cell count for leucopenia and <150 x 109/l of platelet count for thrombocytopenia). Results: A greater number of the subjects had anaemia with prevalence ranging from 78% at the onset to 100% by the fifth course. Leucopenia ranged from 14% at the beginning to 100% by the third course. Thrombocytopenia was not present at pre-chemotherapy stage but appeared slightly (4%) during the assessment for second treatment course and rose to 55% at the last assessment. Conclusion: This study observed increasing proportions of cytopenia in association with progressing chemotherapy. There is high prevalence of anaemia in breast cancer even before commencement of chemotherapy, while leucopenia develops more rapidly during chemotherapy.\",\"PeriodicalId\":380612,\"journal\":{\"name\":\"African Journal of Laboratory Haematology and Transfusion Science\",\"volume\":\"37 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-03-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"African Journal of Laboratory Haematology and Transfusion Science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.59708/ajlhts.v2i2.2309\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"African Journal of Laboratory Haematology and Transfusion Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.59708/ajlhts.v2i2.2309","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
简介:贫血、白细胞减少和血小板减少是在乳腺癌管理中遇到的血液学紊乱的最前沿。然而,关于它们在化疗不同阶段的发生程度的知识还存在差距。方法:采用纵向设计和目的抽样技术,在尼日利亚克罗斯河州卡拉巴尔市卡拉巴尔大学教学医院接受化疗的50例成年女性乳腺癌患者。获得了伦理批准和知情同意。血细胞计数由自动化完成。使用年龄和性别特异性参考范围(血红蛋白浓度<120 g/l为贫血,白细胞总数<4.0 x 109/l为白细胞减少,血小板计数<150 x 109/l为血小板减少)应用截断点后计算贫血、白细胞减少和血小板减少的频率。结果:更多的受试者出现贫血,患病率从开始时的78%到第5个疗程时的100%。白细胞减少从开始时的14%到第三疗程时的100%不等。化疗前未出现血小板减少,但在第二次疗程评估时略有出现(4%),最后一次评估时上升至55%。结论:本研究观察到随着化疗的进展,细胞减少的比例增加。即使在化疗开始之前,乳腺癌中贫血的发生率也很高,而化疗期间白细胞减少的发生率更高。
Proportions of Blood Cell Deficits in Breast Cancer Patients Undergoing Chemotherapy
Introduction: Anaemia, leucopenia and thrombocytopenia are at the forefront of haematological derangements encountered in the management of breast cancer. However, there is a gap in knowledge regarding their degree of occurrence at different stages of chemotherapy. Methods: Longitudinal design and purposive sampling technique were adopted to enroll 50 adult female breast cancer patients who were accessing chemotherapy at the University of Calabar Teaching Hospital in Calabar, Cross River State of Nigeria. Ethical approval and informed consent were duly obtained. The blood cell counts were carried out by automation. Frequencies of anaemia, leucopenia and thrombocytopenia were calculated after applying cut-off point using age- and gender-specific refence ranges (<120 g/l of Haemoglobin concentration for anaemia, <4.0 x 109/l of total white blood cell count for leucopenia and <150 x 109/l of platelet count for thrombocytopenia). Results: A greater number of the subjects had anaemia with prevalence ranging from 78% at the onset to 100% by the fifth course. Leucopenia ranged from 14% at the beginning to 100% by the third course. Thrombocytopenia was not present at pre-chemotherapy stage but appeared slightly (4%) during the assessment for second treatment course and rose to 55% at the last assessment. Conclusion: This study observed increasing proportions of cytopenia in association with progressing chemotherapy. There is high prevalence of anaemia in breast cancer even before commencement of chemotherapy, while leucopenia develops more rapidly during chemotherapy.